Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018220444) COMPOSITIONS AND METHODS FOR TREATING DRY EYE SYNDROME DELIVERING ANTIBIOTIC MACROLIDE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/220444 International Application No.: PCT/IB2018/000693
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
A61K 31/4355 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
4355
the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
Applicants:
EXIMORE LTD. [IL/IL]; High-tech Village, Givat Ram Campus P.O. Box 39158 91391 Jerusalem, IL
Inventors:
ATTAR, Ishay; IL
SHEETRIT, Eyal; IL
Priority Data:
62/512,68230.05.2017US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING DRY EYE SYNDROME DELIVERING ANTIBIOTIC MACROLIDE
(FR) COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU SYNDROME DE LA KÉRATOCONJONCTIVITE SÈCHE PAR ADMINISTRATION D'UN ANTIBIOTIQUE MACROLIDE
Abstract:
(EN) In some embodiments, the present invention is a method of treating dry eye syndrome, comprising: administering a composition to an eye of a mammal in need thereof; wherein the composition is a sustained release composition; wherein the composition is configured to release an effective amount of an active agent per day for a treatment period of at least seven days; and wherein the active agent is Tacrolimus.
(FR) La présente invention concerne, dans certains modes de réalisation, un procédé de traitement du syndrome de la kératoconjonctivite sèche, comprenant : l'administration d'une composition à un œil d'un mammifère en ayant besoin ; la composition étant une composition à libération prolongée ; la composition étant configurée pour libérer une quantité efficace d'un agent actif par jour pendant une période de traitement d'au moins sept jours ; et l'agent actif étant le Tacrolimus.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)